Pharmacogenomics of Drug Hypersensitivity
Immunology and Allergy Clinics of North America, ISSN: 0889-8561, Vol: 42, Issue: 2, Page: 335-355
2022
- 8Citations
- 13Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations8
- Citation Indexes8
- CrossRef8
- Captures13
- Readers13
- 12
Review Description
Hypersensitivity reactions are caused by many structurally unrelated drugs used for many different diseases. These reactions vary in severity and can be fatal. Only a minority of patients are affected by drug hypersensitivity reactions. Predisposition seems to be mediated by genetic factors, particularly within the HLA system. Apart from HLA-B∗57:01 testing, which is routine to prevent abacavir hypersensitivity, uptake of HLA testing into clinical practice has been slow and challenging. As genomic medicine becomes mainstream, it will be important for genetic testing in this area to move from the current reactive strategy to a more pre-emptive approach.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0889856122000066; http://dx.doi.org/10.1016/j.iac.2022.01.006; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85127530787&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/35469622; https://linkinghub.elsevier.com/retrieve/pii/S0889856122000066; https://dx.doi.org/10.1016/j.iac.2022.01.006
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know